Compare PTCT & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | TFX |
|---|---|---|
| Founded | 1998 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.8B |
| IPO Year | 2006 | 1994 |
| Metric | PTCT | TFX |
|---|---|---|
| Price | $71.41 | $139.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 8 |
| Target Price | $80.65 | ★ $138.75 |
| AVG Volume (30 Days) | ★ 794.0K | 570.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | 0.90 | ★ 2.08 |
| Revenue | $264,734,000.00 | ★ $1,992,713,000.00 |
| Revenue This Year | N/A | $15.97 |
| Revenue Next Year | $17.70 | $5.15 |
| P/E Ratio | $79.77 | ★ $67.77 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $57.08 | $100.18 |
| 52 Week High | $90.87 | $145.00 |
| Indicator | PTCT | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 55.17 |
| Support Level | $67.57 | $128.36 |
| Resistance Level | $73.86 | $145.00 |
| Average True Range (ATR) | 2.00 | 4.12 |
| MACD | 0.17 | 0.23 |
| Stochastic Oscillator | 54.41 | 66.50 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.